JPM 2026: Less talk and more action

DDW Winter 2025/2026

01/22/26

DDW Winter 2025/2026

...

‘Good vibrations’ at London Life Science Week bode well for 2026

ACT appointed to conduct Phase IIa trial of POLB 001

Poolbeg granted FDA ODD for CRS cell therapy

CRS prevention: Taking the sting from CAR-T’s tail

Meet the Researcher: Liam Tremble

The uncapped potential of cancer research (Page 39)

Removing the needle: the unmet need for oral GLP-1 drugs

Treatment potential for immunotherapy-induced CRS

Poolbeg Pharma
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.